Talk:Sulpiride: Difference between revisions
>Chetnik91 m edit2 |
>David Hedlund {{Experience reports|erowid_experience_substance_label=}} |
||
(3 intermediate revisions by 2 users not shown) | |||
Line 10: | Line 10: | ||
==Chemistry== | ==Chemistry== | ||
{{chemistry}} | {{chemistry}} | ||
Sulpiride is a member of the class of benzamides obtained from formal condensation between the carboxy group of 2-methoxy-5-sulfamoylbenzoic acid and the primary amino group of (1-ethylpyrrolidin-2-yl)methylamine. It has a role as an antidepressant, an antiemetic, an antipsychotic agent and a dopaminergic antagonist. | |||
==Pharmacology== | ==Pharmacology== | ||
{{pharmacology}} | {{pharmacology}} | ||
Line 91: | Line 93: | ||
}} | }} | ||
}} | }} | ||
===Experience reports=== | ===Experience reports=== | ||
{{Experience reports| | {{Experience reports|erowid_experience_substance_label=}} | ||
==Toxicity and harm potential== | ==Toxicity and harm potential== | ||
Line 140: | Line 143: | ||
==History and culture== | ==History and culture== | ||
{{historyStub}} | Sulpiride, sold under the brand name Dogmatil among others, is an atypical antipsychotic (although some texts have referred to it as a typical antipsychotic)medication of the benzamide class which is used mainly in the treatment of psychosis associated with schizophrenia and major depressive disorder, and is sometimes used in low dosage to treat anxiety and mild depression. Sulpiride is commonly used in Asia, Central America, Europe, South Africa and South America. Levosulpiride is its purified levo-isomer and is sold in India for similar purposes. It is not approved in the United States, Canada, or Australia. The drug is chemically and clinically similar to amisulpride. | ||
{{historyStub}Sulpiride is marketed under the brand names Dogmatil (DE, HK, SG, PH), Dolmatil (IE, UK, NL), Eglonyl (RU, ZA, HR, SI), Espiride (ZA), Modal (IL), Prometar (UY), Equilid (BR) and Sulpor (UK),Eglonyl(SRB,SLO,CRO,BIH) among many others.}Sulpiride was discovered in 1966 as a result of a research program by Justin-Besançon and C. Laville at Laboratoires Delagrange who were working to improve the anti-dysrhythmic properties of procainamide; the program led first to metoclopramide and later to sulpiride. Laboratoires Delagrange was acquired by Synthelabo in 1991 which eventually became part of Sanofi. | |||
==Chemistry== | ==Chemistry== |